Role of leukemic stem cells in the chronic myeloid leukemia pathogenesis

I Sviezhentseva

Автор(и)

I Sviezhentseva National University "Kyiv-Mohila Academy", Kyiv,

Ключові слова:

leukemic stem cells, chronic myeloid leukemia, hematopoietic stem cell microenvironment.

Анотація

The presence of leukemic stem cells (LSC) in the bone marrow of patients with chronic myeloid leukemia (CML) is the cause of relapses as a result of the treatment with chemotherapeutic agents and target therapy drugs. This is due to the ability of LSC to attach itself to the microenvironment cells and to remain at rest for a long time. Vascular and osteoblasts niche play a very important role in this process. However, for being in G0 phase LSC have direct contact with the cellular elements of bone marrow microenvironment. So LSK contact with mesenchymal cells of bone marrow using the appendixes, connecting components invaginations and lint. The cadherins and integrins are important in the interaction of osteoblasts niche. They are able to activate intracellular signaling cascades that provide resting state of LSK. In addition, a bone marrow niche provides changes of LSC oxidative metabolism, which also plays an important role for cell entry into the G0 phase. Further, LSC also have certain physiological properties, which play an important role in the drug resistance formation, particularly drugs with targeted actions - tyrosine kinase inhibitors. LSK characterized by a high level of BCR-ABL expression and their population can have a lot of point mutations in the bcr-abl gene in the same patient. This leads to the fact that the taken medicines dose does not act against LSK, reducing the number of a whole leukemic cells clone. However, complete LSC elimination from the the patient’s bone marrow need search the main differences between the LSC and normal HSC. After the literature analysis it was found that LSC have several significant differences such as the ability to cause leukemia during the transplantation to immunodeficient animals, this leukemia is morphologically and phenotypically similar to the original tumor, in addition the LSC can be transmitted from animal to animal. In addition, the LSC is also characterized by the mutations presence in the genes of kinase domains, transcription factors and tumor suppressors (genes of growth factors FLT3, C-KIT, genes K-RAS and N-RAS, mutations in genes STAT5A, TP53, AML1, RB1, MYC, p16 / NK4a, ENV1). Now the most important role in LSK biology research takes studying of signaling cascades involved in the processes of cell activity. This key molecule of cell signaling pathways can become targeted agents that may be used for the elimination of LSC from the patient bone marrow. However, it is necessary to distinguish the molecular cascades that are inherent to all bone marrow stem cells from LSC specific intracellular signal transmittors. Common to the LSC and HSC are the following signaling pathways: Wnt/β-catenin, Sonic Hedgehog and Noch signaling pathways. Moreover, there are signaling cascades that are specific only for LSC. They are charecterized by the exclusive expression of Alox5, AHI-1 and NFκB genes. In addition, the LSC are also characterized by the increased expression of AVSV-1 and ABCG-2 transporters, providing the evacuation of the cell chemotherapeutic drugs. LSC are characterized by the decreased expression of Oct-4, which ensures the supply of drugs to cells. The article also highlights the key therapeutic tactics that can be used to eliminate the recurrence of CML associated with the presence of LSC, which remain at rest for a long time, in the bone marrow of patients. The first tactic is elimination of LSC using the targeted drugs that operate solely on the target molecule in leukemic cells. The second approach is a direct administration of drugs to a patient that could promote a permanent state of rest for LSC in order to prevent relapses

Посилання

Buss, E. C. Leukemia stem cells / E. C. Buss, A. D. Ho // Int. J. of Cancer. – 2011. Vol. 129. – P. 2328 – 2336.

Gluzman, D. F. Evolution of leukemic stem cells in chronic myeloid leukemia / D. F. Gluzman, L. M. Sklyarenko, T. S. Ivanovskaya [at all] // Laboratory diagnostic. – 2013. – Vol. 3, № 65. – Р. 50 – 54.

Nwajei, F. The Bone Marrow Microenvironment as Niche Retreats for Hematopoietic and Leukemic Stem Cells / F. Nwajei, M. Konopleva // Advances in Hematology. – 2013. - Vol. 2013. – P. 1 – 8.

Drize, N. I. The differences between normal and leukemic hematopoietic stem cells / N. I. Drize // Hematology. – 2006. – Vol. 2. – P. 5 – 9.

Bing Z. Carter The elusive CML stem cell: does it matter and how do we eliminate it? / Bing Z. Carter, Duncan D. Mak, Jorge Cortes, at al. // Semin Hematol. – 2010. – Vol 47, № 4. – P. 362 – 370.

Buss, E. C. Leukemia stem cells / E.C. Buss, A.D. Ho // International Journal of Cancer. – 2011. – Vol. 129. – P. 2328 – 2336.

Craig T. Jordan. The leukemic stem cell / Craig T. Jordan // Best Pract Res Clin Haematol. – 2007. – Vol. 20, № 1. – Р. 13 – 18.

Park, C.Y. Cancer stem cell-directed therapies: recent data from the laboratory and clinic / C.Y. Park, D. Tseng, I.L. Weissman // Mol. Ther. – 2009. – Vol. 17, № 2. – Р. 219 – 223.

Seke Etet, P.F. Signaling pathways in chronic myeloid leukemia and leukemic stem cell maintenance: Key role of stromal microenvironment / P.F. Seke Etet, L. Vecchio, A.H. Nwabo Kamdje // Cellular Signalling. – 2012. – Vol. 24. – P. 1883 – 1888.

Chomel, J.C. Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy / J.C. Chomel, A.G., Turhan // Oncotarget. – 2011. – Vol 2, № 9. – P. 713 – 727.

Luo, L. Leukemia Stem Cells / L. Luo, Z. Chao Han // International Journal of Hematology. – 2006. – Vol. 8. – P. 124 – 127.

Jamieson, C.H.Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML / C.H. Jamieson, L.E. Ailles, S.J. Dylla, [et all] // N Engl. J. Med. – 2004. – Vol. 351. – P. 657 – 667.

Zhao, C. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia / C. Zhao, A. Chen, C. H. Jamieson, [et all] // Nature. – 2009. – Vol. 458. – P. 776 – 779.

Babashah, S.Targeting of the signal transducer Smo links microRNA-326 to the oncogenic Hedgehog pathway in CD341 CML stem/progenitor cells / S. Babashah, M. Sadeghizadeh, A. Hajifathali // Int. J. of Cancer. – 2013. – Vol. 133. – P. 579 – 590.

Merkerova, M. Bmi-1 over-expression plays a secondary role in chronic myeloid leukemia transformation / M. Merkerova, H. Bruchova, A. Kracmarova, [at all] // Leuk Lymphoma. – 2007. – Vol. 48, № 4. – P. 793 – 801.

Roboz, G.J. Acute myeloid leukemia stem cells: seek and destroy / G. J. Roboz, M. Guzman // Expert Rev Hematol. – 2009. – Vol. 2. – P. 663 – 672.

Nakahara, F. Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia / F. Nakahara, M. Sakata-Yanagimoto, Y. Komeno, [еt all] // Blood. – 2010. – Vol. 115. – P. 2872 – 2881.

Pardal, R. Applying the principles of stem-cell biology to cancer / Pardal R., Clarke M.F., Morrison S.J. // Nat. Rev. Cancer. – 2003. – Vol. 3, № 12. – P. 895 – 902.

Donato, N.J. Chronic myeloid leukemia stem cells and developing therapies / N. J. Donato, L. F. Peterson // Leukemia & Lymphoma. – 2011. – Vol. 52. – P. 60 – 80.

Warsch, W. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia / W. Warsch, K. Kollmann, E. Eckelhart // Blood. – 2011. – Vol. 117. – P. 3409 – 3420.

Guzman, M.L. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells / M. L. Guzman, R. M. Rossi, L. Karnischky [et al] // Blood. – 2005. – Vol. 105. – P. 4163 – 4169.

Rajesh, R. Hazlehurst The bone marrow microenvironment as a sanctuary for minimal residual disease in CML / R. Nair Rajesh, J. Tolentino, A. Lori // Biochemical Pharmacology. – 2010. – Vol. 80. – P. 602 – 612.

Mayani, H. In vitro biology of human myeloid leukemia / H. Mayani, E. Flores-Figueroa, A. Chavez-Gonzalez // Leukemia Research. – 2009. – Vol. 33. – P. 624 – 637.

Craig, T. J. The leukemic stem cell / Craig // Best. Pract. Res. Clin. Haematol. – 2007. – Vol. 20, № 1. – P. 13 – 18.

Konopleva, M. Y. Leukemia Stem Cells and Microenvironment: Biology and Therapeutic Targeting / M. Y. Konopleva, C.T Jordan // J. of Clin. Oncol. – 2011. – Vol. 29, № 5. – P. 591 – 599.

Colmone, A. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells / A. Colmone, M. Amorim, A.L. Pontier, [et all] // Science. – 2008. – Vol. 322. – P. 1861 – 1865.

Essers, M. A. IFNalpha activates dormant haematopoietic stem cells in vivo / M. A. Essers, S. Offner, W. E. Blanco-Bose, [et all] // Nature. – 2009. – Vol. 458. – P. 904 – 908.

Wagner, W. Hematopoietic progenitor cells and cellular microenvironment: behavioral and molecular changes upon interaction / W. Wagner, R. Saffrich, U. Wirkner // Stem Cells. – 2005. – Vol. 23. – P. 1180 –1191.

Zeng, Z. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML / Z. Zeng, Y. X. Shi, I. J. Samudio // Blood. – 2009. – Vol. 113. – P. 6215 – 6224.

Nwajei, F. The Bone Marrow Microenvironment as Niche Retreats for Hematopoietic and Leukemic Stem Cells / F. Nwajei, M. Konopleva // Adv. in Hematol. – 2013. Vol. 2013. – P. 1 – 8.

Ninomiya, M. Homing, proliferation and survival sites of human leukemia cells in vivo in immunode eficient mice / M. Ninomiya, A. Abe, A. Katsumi [et all] // Leukemia. – 2007. – Vol. 21, № 1. – P. 136 – 142.

Mayerhofer, M. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1????, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin / M. Mayerhofer, P. Valent, W.R. Sperr // Blood. – 2002. – Vol. 100, - № 10. – P. 3767 – 3775.

Eliasson, P. The hematopoietic stem cell niche: low in oxygen but a nice place to be / P. Eliasson, J. I. Jonsson // J. Cell Physiol. – 2010. – Vol. 222. – P. 17 – 22.

Mohyeldin, A. Oxygen in stem cell biology: a critical component of

the stem cell niche / A. Mohyeldin, T. Garzo?n-Muvdi, A. Quin? ones-Hinojosa // Cell Stem Cell. – 2010. – Vol. 7. – P. 150 – 161.

Jin, L. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells / L. Jin, Y. Tabe, S. Konoplev, [et all] // Mol. Cancer. Ther. – 2008. – Vol. 7. – P. 48 – 58.

Peng, C. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells / C. Peng, J. Brain, Y. Hu, [et all] // Blood. – 2007. Vol. 110. – P. 678 – 685.

Ishikawa, F. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice / F. Ishikawa, M. Yasukawa, B. Lyons, [et all] // Blood. – 2005. – Vol. 106. – P. 1565 – 1573.